National Bank of Canada
KYTX icon

National Bank of Canada’s Kyverna Therapeutics KYTX Stock Holding History

National Bank of Canada’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.45K Hold
400
– – ﹤0.01% 2526
2025
Q4 		$3.76K Buy
+400
New +$2.97K ﹤0.01% 2484

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

National Bank of Canada's KYTX Position: Q1 2026 in Review

National Bank of Canada held its Kyverna Therapeutics (KYTX) position steady in Q1 2026 at 400 shares worth $3.45K. The position accounts for ﹤0.01% of the portfolio, ranked #2526.

National Bank of Canada first reported a position in KYTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $3.76K in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • National Bank of Canada held 400 shares of Kyverna Therapeutics worth $3.45K as of Q1 2026.
  • National Bank of Canada left its Kyverna Therapeutics share count unchanged in Q1 2026.
  • Kyverna Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2526 holding.
  • National Bank of Canada first reported a position in Kyverna Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • National Bank of Canada's Kyverna Therapeutics position peaked at $3.76K in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.